Chronic cannabis use downregulates CB1 receptors, which may mirror changes seen in psychosis

The first systematic review of how cannabis affects the endocannabinoid system found chronic use downregulates CB1 receptors, a pattern that may overlap with endocannabinoid changes seen in psychosis, though the evidence in cannabis users with schizophrenia is unclear.

Jacobson, Maya R et al.·European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2019·Moderate EvidenceSystematic Review
RTHC-02088Systematic ReviewModerate Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The most established finding is CB1 receptor downregulation after chronic and recent cannabis exposure. This pattern may mirror endocannabinoid system changes observed in psychosis. However, it remains uncertain whether CB1 downregulation also occurs in cannabis users who have schizophrenia.

Key Numbers

CB1 receptor downregulation is the most consistently reported change after chronic cannabis use. The pattern overlaps with endocannabinoid alterations observed in psychosis. Uncertainty remains for cannabis users with schizophrenia.

How They Did This

Systematic review of studies examining the effects of exogenous cannabinoids on the endocannabinoid system in humans with and without psychotic disorders.

Why This Research Matters

If cannabis causes endocannabinoid system changes that resemble those seen in psychosis, this provides a biological mechanism linking cannabis use to psychotic disorders. Understanding this overlap could inform both prevention and treatment.

The Bigger Picture

The endocannabinoid system may be a convergence point where cannabis exposure and psychosis vulnerability meet. If CB1 downregulation is both a consequence of cannabis use and a feature of psychosis, it could explain why cannabis increases psychosis risk in vulnerable individuals.

What This Study Doesn't Tell Us

Limited number of human studies examining endocannabinoid system changes after cannabis use. Unclear whether CB1 changes are cause or effect in psychosis. Different imaging and measurement methods across studies complicate comparison.

Questions This Raises

  • ?Does CB1 downregulation recover with abstinence?
  • ?Is the overlap between cannabis-induced and psychosis-related endocannabinoid changes causal or coincidental?
  • ?Could measuring CB1 receptor density identify individuals at risk for cannabis-related psychosis?

Trust & Context

Key Stat:
Chronic cannabis use downregulates CB1 receptors, potentially mirroring psychosis-related changes
Evidence Grade:
Moderate: first systematic review on this topic, but limited by the small number of available human studies.
Study Age:
Published in 2019.
Original Title:
A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.
Published In:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 29(3), 330-348 (2019)
Database ID:
RTHC-02088

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Does cannabis permanently change brain receptors?

Chronic cannabis use downregulates CB1 receptors, meaning the brain produces fewer of them. Whether this fully reverses with abstinence is still being studied. The pattern is concerning because it overlaps with receptor changes seen in psychosis.

Could this explain why cannabis triggers psychosis?

Possibly. If cannabis causes the same type of endocannabinoid system changes that are seen in psychotic disorders, it could push vulnerable individuals past a biological threshold. But the evidence is still correlational, not causal.

Read More on RethinkTHC

Cite This Study

RTHC-02088·https://rethinkthc.com/research/RTHC-02088

APA

Jacobson, Maya R; Watts, Jeremy J; Boileau, Isabelle; Tong, Junchao; Mizrahi, Romina. (2019). A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 29(3), 330-348. https://doi.org/10.1016/j.euroneuro.2018.12.014

MLA

Jacobson, Maya R, et al. "A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.." European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2019. https://doi.org/10.1016/j.euroneuro.2018.12.014

RethinkTHC

RethinkTHC Research Database. "A systematic review of phytocannabinoid exposure on the endo..." RTHC-02088. Retrieved from https://rethinkthc.com/research/jacobson-2019-a-systematic-review-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.